SolaranRx is developing a precision theranostic platform combining therapeutics and diagnostics for metastatic melanoma. Its lead product, SRX-1177, is a novel peptide linked to a radioisotope that specifically targets melanocortin-1 (MC1) receptors, which are over-expressed in about 80% of melanoma cells. SRX-1177 can identify MC1-positive patients using a standard imaging procedure, after which therapeutic doses are used to deliver targeted radiation to kill melanoma cells while minimizing impact on healthy tissue. Les Stewart and co-founder Stuart Rose acquired exclusive rights to the UNM technology in June 2014 and are advancing the program toward clinical application. The FDA has granted orphan drug status to SRX-1177, and Informa/Kantar Health named it among the 2014 Top 10 Most Interesting Oncology Projects to Watch. Financially, the company recently received a $100,000 investment from the STC.UNM Co-Investment Fund to support continued development.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

May 2015